This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baxter, N. N. Articles by Tuttle, T. M. Search for Related Content PubMed PubMed Citation Articles by Baxter, N. N. Articles by Tuttle, T. M.

Trends in the Treatment and Outcome of Pancreatic Cancer in the United States

¹ Division of General Surgery, St Michael’s Hospital, University of Toronto, Toronto, Canada
² Division of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN, USA

Correspondence: Address correspondence and reprint requests to: Todd M. Tuttle, MD, MS, Division of Surgical Oncology, Department of Surgery, University of Minnesota, 420 Delaware St. SE, Minneapolis, MN 55455, USA; E-mail: tuttl006{at}umn.edu

Background: Although pancreatic cancer is the fourth leading cause of cancer death, few studies have evaluated population-based trends in diagnosis, management, and outcome.

Methods: We used the Surveillance, Epidemiology, and End Results (SEER) registry to evaluate treatment trends and outcomes for patients 18 or older with pancreatic adenocarcinoma diagnosed from 1988 through 2002.

Results: We identified 38,073 patients diagnosed with pancreatic cancer over this 15-year period; the age-adjusted incidence did not change over this period. Most patients were diagnosed with metastatic disease (50.3%), few of whom underwent irradiation or cancer-directed surgery (CDS). For patients with localized or regional disease (32.9%), 53% underwent some form of treatment. Importantly, the rate of CDS increased from 19% in 1988 to 35% in 2002 (P < 0.0001). In multivariate analysis, young age, married status, and localized disease were associated with significantly higher CDS rates. For patients with nonmetastatic disease, 2-year survival rate increased from 8% in 1988 to 15% in 2000. For patients with non-metastatic cancer who survived at least 3 months, CDS was associated with a significantly higher 2-year survival rate (CDS, 36%; non-CDS, 10%). Conclusions: Most patients with pancreatic cancer, even at the end of our 15-year study period, still presented with metastatic disease, and the survival rate for such patients did not change in a meaningful way over time. The proportion of patients with nonmetastatic pancreatic cancer who underwent potentially curative surgery increased over time in the U.S.; the 2-year survival rate for such patients improved, but remained poor.

Key Words: pancreatic cancer • population • treatment • trends

This article has been cited by other articles:

				K. Asomaning, A. E. Reid, W. Zhou, R. S. Heist, R. Zhai, L. Su, E. L. Kwak, L. Blaszkowsky, A. X. Zhu, D. P. Ryan, et al. MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and Prognosis Clin. Cancer Res., June 15, 2008; 14(12): 4010 - 4015. [Abstract] [Full Text] [PDF]